Pluri (PLUR) Short term Debt (2025)

Pluri (PLUR) posted quarterly Short term Debt of $27.8 million for Q4 2025, up 0.88% quarter-over-quarter from $27.5 million in Q3 2025.

Pluri (PLUR) Short term Debt (2025) Analysis & Trends

Pluri (PLUR) has reported Short term Debt for 1 consecutive years, with $27.8 million the latest figure, recorded in Q4 2025.

In Q4 2025, Short term Debt changed N/A year-over-year to $27.8 million; the TTM figure through Dec 2025 stood at $27.8 million (changed N/A YoY), while the FY2025 annual figure was $27.3 million, changed N/A from the prior year.
Short term Debt advanced to $27.8 million in Q4 2025 per PLUR's latest filing, from $27.5 million in the prior quarter.
Across five years, Short term Debt topped out at $27.8 million in Q4 2025 and bottomed at $27.3 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Pluri	16.11 Mn	3.63 Mn	86,000.00

Download Data